🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs Addiction Counsellors of Ireland Launch Strategic Plan 2026–2029 to Prepare for CORU Regulation Ireland Funds €426,000 Behavioral App for Alcohol Reduction Amid Record Treatment Demand A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs Addiction Counsellors of Ireland Launch Strategic Plan 2026–2029 to Prepare for CORU Regulation Ireland Funds €426,000 Behavioral App for Alcohol Reduction Amid Record Treatment Demand
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 04 Jul 2026 · HPRA open data

Irish Medicines Database

Every medicine authorised for the Irish market — 10,165 products with active substances, licence holders, dosage forms and prescription status.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9
491 results for “Novo”
MedicineActive substanceLicence holderStatus
Quentiax SR 200 mg prolonged-release tablets
PA1347/045/002
Quetiapine KRKA, d.d., Novo mesto Marketed
Quentiax SR 300 mg prolonged-release tablets
PA1347/045/003
Quetiapine hemifumarate KRKA, d.d., Novo mesto Marketed
Quentiax SR 400 mg prolonged-release tablets
PA1347/045/005
Quetiapine hemifumarate KRKA, d.d., Novo mesto Marketed
Quentiax SR 50 mg prolonged-release tablets
PA1347/045/004
Quetiapine KRKA, d.d., Novo mesto Marketed
Quetiapine Krka 100mg Film-coated Tablets
PA1347/027/002
Quetiapine KRKA, d.d., Novo mesto Marketed
Quetiapine Krka 200mg Film-coated Tablets
PA1347/027/003
Quetiapine KRKA, d.d., Novo mesto Marketed
Quetiapine Krka 25mg Film-coated Tablets
PA1347/027/001
Quetiapine KRKA, d.d., Novo mesto Marketed
Quetiapine Krka 300mg Film-coated Tablets
PA1347/027/004
Quetiapine KRKA, d.d., Novo mesto Marketed
Rabeprazole Krka 10mg Gastro-Resistant Tablets
PA1347/030/001
Rabeprazole sodium KRKA, d.d., Novo mesto Marketed
Rabeprazole Krka 20mg Gastro-Resistant Tablets
PA1347/030/002
Rabeprazole sodium KRKA, d.d., Novo mesto Marketed
Ramipril Krka 1.25 mg tablets
PA1347/042/001
Ramipril KRKA, d.d., Novo mesto Marketed
Ramipril Krka 10 mg tablets
PA1347/042/004
Ramipril KRKA, d.d., Novo mesto Marketed
Ramipril Krka 2.5 mg tablets
PA1347/042/002
Ramipril KRKA, d.d., Novo mesto Marketed
Ramipril Krka 5 mg tablets
PA1347/042/003
Ramipril KRKA, d.d., Novo mesto Marketed
Ranolazine Krka 375 mg prolonged-release tablets
PA1347/109/001
Ranolazine KRKA, d.d., Novo mesto Marketed
Ranolazine Krka 500 mg prolonged-release tablets
PA1347/109/002
Ranolazine KRKA, d.d., Novo mesto Marketed
Ranolazine Krka 750 mg prolonged-release tablets
PA1347/109/003
Ranolazine KRKA, d.d., Novo mesto Marketed
Rasagiline Krka 1 mg tablets
PA1347/088/001
Rasagiline KRKA, d.d., Novo mesto Marketed
Refixia 1 000 IU powder and solvent for solution for injection
EU/1/17/1193/002
Nonacog beta pegol Novo Nordisk A/S
Refixia 2 000 IU powder and solvent for solution for injection
EU/1/17/1193/003
Nonacog beta pegol Novo Nordisk A/S
Refixia 3 000 IU powder and solvent for solution for injection
EU/1/17/1193/004
Nonacog beta pegol Novo Nordisk A/S
Refixia 500 IU powder and solvent for solution for injection
EU/1/17/1193/001
Nonacog beta pegol Novo Nordisk A/S
Repaglinide Krka 0.5 mg tablets
EU/1/09/579/1-6
Repaglinide KRKA, d.d., Novo mesto
Repaglinide Krka 1 mg tablets
EU/1/09/579/7-12
Repaglinide KRKA, d.d., Novo mesto
Repaglinide Krka 2 mg tablets
EU/1/09/579/13-18
Repaglinide KRKA, d.d., Novo mesto
Rivaroxaban Krka 10 mg film-coated tablets
PA1347/098/002
Rivaroxaban KRKA, d.d., Novo mesto Marketed
Rivaroxaban Krka 15 mg film-coated tablets
PA1347/098/003
Rivaroxaban KRKA, d.d., Novo mesto Marketed
Rivaroxaban Krka 2.5 mg film-coated tablets
PA1347/098/001
Rivaroxaban KRKA, d.d., Novo mesto Not marketed
Rivaroxaban Krka 20 mg film-coated tablets
PA1347/098/004
Rivaroxaban KRKA, d.d., Novo mesto Marketed
Rolpryna SR 2 mg prolonged-release tablets
PA1347/012/001
Ropinirole hydrochloride KRKA, d.d., Novo mesto Marketed
Rolpryna SR 4 mg prolonged-release tablets
PA1347/012/002
Ropinirole hydrochloride KRKA, d.d., Novo mesto Marketed
Rolpryna SR 8 mg prolonged-release tablets
PA1347/012/003
Ropinirole hydrochloride KRKA, d.d., Novo mesto Marketed
Rosuvastatin Krka 10 mg film-coated tablets
PA1347/016/002
Rosuvastatin KRKA, d.d., Novo mesto Marketed
Rosuvastatin Krka 20 mg film-coated tablets
PA1347/016/003
Rosuvastatin KRKA, d.d., Novo mesto Marketed
Rosuvastatin Krka 40 mg film-coated tablets
PA1347/016/004
Rosuvastatin KRKA, d.d., Novo mesto Marketed
Rosuvastatin Krka 5 mg film-coated tablets
PA1347/016/001
Rosuvastatin KRKA, d.d., Novo mesto Marketed
Rosuvastatin/Ezetimibe KRKA 10 mg/10 mg Film-Coated Tablets
PA1347/108/001
Rosuvastatin calcium, Ezetimibe KRKA, d.d., Novo mesto Marketed
Rosuvastatin/Ezetimibe KRKA 20 mg/10 mg Film-Coated Tablets
PA1347/108/002
Rosuvastatin calcium, Ezetimibe KRKA, d.d., Novo mesto Marketed
Rosuvastatin/Ezetimibe Krka 40 mg/10 mg film-coated tablets
PA1347/108/003
Rosuvastatin calcium, Ezetimibe KRKA, d.d., Novo mesto Marketed
Rybelsus 1.5 mg tablets
EU/1/20/1430/016-020
Semaglutide Novo Nordisk A/S
Rybelsus 14 mg tablets
EU/1/20/1430/008-010
Semaglutide Novo Nordisk A/S
Rybelsus 25 mg tablets
EU/1/20/1430/031-035
Semaglutide Novo Nordisk A/S
Rybelsus 3 mg tablets
EU/1/20/1430/001-004
Semaglutide Novo Nordisk A/S
Rybelsus 4 mg tablets
EU/1/20/1430/021-025
Semaglutide Novo Nordisk A/S
Rybelsus 50 mg tablets
EU/1/20/1430/036-040
Semaglutide Novo Nordisk A/S
Rybelsus 7 mg tablets
EU/1/20/1430/005-007
Semaglutide Novo Nordisk A/S
Rybelsus 9 mg tablets
EU/1/20/1430/026-030
Semaglutide Novo Nordisk A/S
Ryzodeg 100 units/mL solution for injection
EU/1/12/806/1,4,5,7,8
Insulin degludec (ideg), Insulin aspart Novo Nordisk A/S
Sacubitril/Valsartan Krka 24 mg/26 mg film-coated tablets
PA1347/119/001
Sacubitril sodium, Valsartan disodium KRKA, d.d., Novo mesto Not marketed
Sacubitril/Valsartan Krka 49 mg/51 mg film-coated tablets
PA1347/119/002
Sacubitril sodium, Valsartan disodium KRKA, d.d., Novo mesto Not marketed
5 6 7 8 9 10

Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.